CIITA anticorps (AA 706-755)
-
- Antigène Voir toutes CIITA Anticorps
- CIITA (Class II, Major Histocompatibility Complex, Transactivator (CIITA))
-
Épitope
- AA 706-755
-
Reactivité
- Humain, Souris, Rat
-
Hôte
- Lapin
-
Clonalité
- Polyclonal
-
Conjugué
- Cet anticorp CIITA est non-conjugé
-
Application
- Western Blotting (WB), ELISA
- Specificité
- CIITA Antibody detects endogenous levels of total CIITA protein.
- Purification
- Immunoaffinity purified
- Immunogène
-
Synthetic peptide from human CIITA (aa706-755).
Type of Immunogen: Synthetic peptide - Isotype
- IgG
- Top Product
- Discover our top product CIITA Anticorps primaire
-
-
- Indications d'application
- Approved: Peptide-ELISA (1:10000), WB (1:500 - 1:1000)
- Commentaires
-
Target Species of Antibody: Human
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- Lot specific
- Buffer
- PBS (without Mg2+, Ca2+), pH 7.4, 150 mM sodium chloride, 0.02 % sodium azide, 50 % glycerol
- Agent conservateur
- Sodium azide
- Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Stock
- -20 °C
- Stockage commentaire
- Store at -20°C for up to 1 year.
- Date de péremption
- 12 months
-
- Antigène
- CIITA (Class II, Major Histocompatibility Complex, Transactivator (CIITA))
- Autre désignation
- CIITA (CIITA Produits)
- Synonymes
- anticorps CIITA, anticorps C2ta, anticorps EG669998, anticorps Gm9475, anticorps C2TA, anticorps CIITAIV, anticorps MHC2TA, anticorps NLRA, anticorps Mhc2ta, anticorps class II, major histocompatibility complex, transactivator, anticorps class II major histocompatibility complex transactivator, anticorps MHC class II transactivator, anticorps class II transactivator, anticorps CIITA, anticorps LOC710761, anticorps ciita, anticorps LOC100443575, anticorps Ciita, anticorps LOC100736732
- Sujet
-
Name/Gene ID: CIITA
Synonyms: CIITA, C2TA, MHC class II transactivator, MHC2TA, CIITAIV, NLRA - ID gène
- 4261
- UniProt
- P33076
- Pathways
- Cancer Immune Checkpoints
-